Institut Pasteur de Lille
Institut Pasteur de Lille is a 130-year-old non-profit biomedical research foundation in Lille, France, with 800+ researchers across 8 units conducting research on infectious, metabolic, and neurodegenerative diseases. It generates revenue through donations, research grants, biotech partnerships, prevention services, and corporate sponsorship.
- Company typePrivate
- Founded1894
- HeadquartersLille, France
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
What Institut Pasteur de Lille does
Institut Pasteur de Lille is a private, non-profit foundation recognized as a public utility since 1898, headquartered at 1 Rue du Professeur Calmette in Lille, France. Founded in 1894 by Albert Calmette in response to a diphtheria epidemic, the institute is credited with developing the BCG tuberculosis vaccine in 1921 and operates 800+ personnel across 34 research teams organized into 8 specialized research units covering infectious diseases, metabolic diseases (diabetes, obesity), cancer, neurodegenerative diseases (Alzheimer's), cardiovascular diseases, and antibiotic resistance. It hosts a Drug Discovery Center, multiple shared technology platforms (BICeL bioimaging/cytometry, ARIADNE high-content screening, P3M proteomics, NMR, LIGAN MP genomics, Bille bioinformatics, TAG transcriptomics), and incubates biotech startups on campus including Bioversys, StarkAge Therapeutics, Genoscreen, Apteeus, 4P-Pharma, and Immune Insight.
The institute generates revenue across five distinct streams: individual donations and bequests (with 66% tax deduction), institutional research grants from CNRS, INSERM, University of Lille, and European programs, biotech licensing and facility sharing with campus startups, corporate sponsorship, and prevention services. The prevention arm operates a WHO-accredited International Vaccination Center (since 1951), a preventive health checkup center, and a rabies center across four regional locations (Lille, Tourcoing, Arras, Béthune), with appointments managed via Doctolib and Omnidoc. Additional offerings include the Longevity Path preventive medicine program, the Pasteur Institute Museum, the Le 1894 event venue, the Kid Campus science education program for CM1-CM2 students, and the Vipali digital health prevention tool launched in 2023.
The institute is governed by a Board of Directors including representatives from regional institutional partners (European Metropolis of Lille, Hauts-de-France Regional Council, Nord Departmental Council) and is led by Director General Frédéric Batteux (appointed September 2024) and Deputy Director General Perrine Quivron (appointed December 2024). It operates independently but coordinates the Europe region of the International Network of Pasteur Institutes (RIIP), comprising 32 institutes across 25 countries, and maintains active research collaborations with University of Lille, Imperial College London, CNRS, INSERM, and CHU de Lille.
Institut Pasteur de Lille firmographics
Firmographics- Name
- Institut Pasteur de Lille
- Legal name
- Institut Pasteur de Lille
- Website
- https://pasteur-lille.fr
- Company type
- Private
- Founded year
- 1894
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Institut Pasteur de Lille is a 130-year-old non-profit biomedical research foundation in Lille, France, with 800+ researchers across 8 units conducting research on infectious, metabolic, and neurodegenerative diseases. It generates revenue through donations, research grants, biotech partnerships, prevention services, and corporate sponsorship.
- Ownership category
- akta.pro rank
Institut Pasteur de Lille industry classification
Industry- Product category
- Biomedical Research and Preventive Healthcare Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Health Care and Social Assistance (62), Voluntary Health Organizations (813212), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Health Services (8000), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)
- akta.pro secondary industries
- Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), National/State/Local Immunization Program Offices (HLAJAHAA), Chronic Disease Prevention & Health Promotion Departments (HLAJAAAN), Non-Communicable Disease Prevention & Chronic Disease Programs (BPAIAJAI)
Keywords
Where Institut Pasteur de Lille is headquartered
LocationHeadquarters
- HQ city
- Lille
- HQ country
- France
- HQ region
- Europe
Offices5 records
Markets served
Institut Pasteur de Lille business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
Revenue model
- Donations and charitable contributions: Individual donations, bequests, and legacies from supporters. The institute receives tax-deductible donations with 66% tax reduction for individuals.
- Biotechnology company partnerships: Revenue from biotech startups hosted on campus including Bioversys, StarkAge Therapeutics, Genoscreen, Apteeus, 4P-Pharma, and Immune Insight through licensing, co-development, and facility sharing arrangements.
- Prevention and healthcare services: Revenue from vaccination center, health checkups, and preventive medicine services offered to individuals and enterprises
- Corporate sponsorship and mecenat: Corporate sponsorship programs where companies support research in exchange for association with the institute
- Institutional research funding: Funding from public institutions including CNRS, INSERM, University of Lille, and European research grants
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Vaccination services at the International Vaccination Center |
| Unit Pricing | Pay-as-you-go | Health checkups and preventive examinations |
| Unit Pricing | Pay-as-you-go | Museum admission |
| Other | One-time | Donation amounts suggested on website |
Go-to-market motion1 record
Distribution channels6 records
Marketing channels12 records
Institut Pasteur de Lille product offering
Product offeringCore offering
Institut Pasteur de Lille is a non-profit research foundation that conducts fundamental and applied biomedical research in infectious diseases (notably vaccinology and respiratory pathogens), nutrition/metabolic disorders (diabetes, obesity, cardio-metabolic disease), and neurodegenerative diseases (Alzheimer's and related dementias). It complements this research with a Center for Preventive Medicine that delivers individual health check-ups, a Clinical Investigation Center supporting clinical trials, and the SH2 center for human and social sciences, while also running training programs and public-health outreach actions.
Product overview
Institut Pasteur de Lille is a private, non-profit research foundation recognized as a public utility since 1898, operating as an integrated research and healthcare institution. The organization offers a combination of clinical healthcare services (international vaccination center, preventive health checkups, rabies center), research infrastructure (Drug Discovery Center, technological platforms for genomics, proteomics, bioinformatics, and screening), and public engagement (museum, educational programs like Kid Campus, and the 1894 event venue). The Institute conducts research across 34 teams organized into 8 units, focusing on areas including infectious diseases, cancers, neurodegenerative diseases, cardiovascular and metabolic diseases, and drug discovery. Key digital offerings include Vipali for personalized health prevention. The institution's preventive health programs, including the Longevity Path initiative, represent an innovative approach to predictive and preventive medicine.
Differentiator
Problem solved
Functional benefit
Products and services
- Center for Preventive Medicine (Centre de Prévention Santé) On-site preventive health service that delivers comprehensive individual health check-ups to adults in the Lille region, covering screening and risk assessment for the diseases studied by the foundation. It serves the general adult population seeking preventive screening.
- Clinical Investigation Center (CIC) Hospital-adjacent clinical research platform supporting translational research and clinical trials across the foundation's three thematic priorities. It serves academic and industry research partners requiring clinical study infrastructure.
- Infectious Diseases and Vaccinology Research Program Core research program focused on respiratory pathogens including SARS-CoV-2 and influenza, with deep expertise in vaccinology. It produces scientific knowledge and vaccine candidates intended for the scientific community and public-health stakeholders.
- Nutrition, Diabetes, Obesity and Cardio-Metabolic Disease Research Program Research program investigating the determinants, mechanisms and prevention of nutrition-related metabolic disorders. It generates scientific publications and translational outputs for the research and public-health community.
- Alzheimer's Disease and Neurodegenerative Disease Research Program Research program dedicated to Alzheimer's disease and related dementias, covering pathogenesis, biomarkers, and prevention strategies. Outputs target the scientific, clinical, and public-health communities.
- SH2 Center for Human and Social Sciences Research and analysis center integrating human and social science perspectives into the foundation's biomedical priorities. It serves public-health stakeholders and policy-oriented decision makers needing behavioral and societal insights.
- University and Academic Training Programs Educational programs offered to students and early-career researchers in partnership with universities, covering biomedical and public-health disciplines aligned with the foundation's research themes.
- Public Health Awareness Campaigns and Outreach Public-facing campaigns, events and educational outreach that translate the foundation's scientific findings into health-promoting messages for the general population, with a focus on the diseases studied by the foundation.
Quantifiable outcome
- 91 genetic regions identified associated with Alzheimer's disease risk, including 16 new regions in European populations
- +4 more outcomes
Companies that use Institut Pasteur de Lille
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Institut Pasteur de Lille technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature7 records
Institut Pasteur de Lille partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core, key and minor.
- International Network of Pasteur Institutes (RIIP)coreThe Institut Pasteur de Lille coordinates the Europe region within the RIIP since November 2018, a three-year strategic mandate. The network comprises 32 institutes in 25 countries united by the mission of protecting human health through research, training, and disease surveillance.
- University of LillecoreJoint research collaborations including Unit U1283/8199 'Multi-omics and pathophysiology of metabolic diseases' and multiple other joint research units combining University, CNRS, Inserm, and Institut Pasteur de Lille researchers.
- Imperial College LondoncoreInternational research collaboration led by Dr. Amna Khamis and Professor Philippe Froguel on pancreatic aging and diabetes research, published in Nature Communications.
- CNRS (National Centre for Scientific Research)coreJoint research units and collaborative research programs including UMR9017, UMR9031, and multiple other CNRS partnerships on the campus.
- INSERM (National Institute of Health and Medical Research)coreJoint research units including UMR1011, UMR1167, UMR1177, UMR1190, UMR1283, and collaborative research across metabolic, cardiovascular, and neurodegenerative disease research.
- CHU de Lille (Lille University Hospital)coreClinical research collaboration and translational research partnership including Joint Research Units U1190 and U1283/8199 focused on diabetes and metabolic diseases.
- Bioversys SASkeyBiotech subsidiary of Swiss company BioVersys AG focused on developing small molecules targeting bacterial resistance. Uses TRIC technology for antibiotic resistance research. Located on campus with R&D activities in Unit U1177.
- GlaxoSmithKline (GSK)keyCollaboration with Bioversys on tuberculosis research programs in preclinical development, as part of GSK's involvement in combating hospital-acquired infections.
- StarkAge TherapeuticskeyPrivate biotechnology startup founded in 2018 focusing on delaying progression of age-related diseases by targeting senescent cell accumulation. Leverages biomarker technology and immunotherapy approaches.
- GenoscreenkeyFrench biotechnology company created on campus in 2001 specializing in genomics analytics and bioinformatics services. Generates over 80% revenue outside Lille metropolitan area with 30% from exports.
- ApteeuskeyInnovative company founded in 2013 specializing in personalized medicine for rare and orphan diseases. Uses miniaturized drug discovery techniques from Unit U1177 for patient-specific drug repurposing screening.
- 4P-PharmakeyClinical-stage biotechnology company launched in 2016 dedicated to developing therapies for serious diseases with unmet medical needs. Led by Dr. Nadira Delhem and Dr. Olivier Moralès.
- Immune InsightkeyStartup offering preclinical drug safety validation services focusing on immune cells and regulatory T lymphocytes. Method directly derived from Pasteur Institute research with internationally recognized unique services.
- LifebloomminorMedical device startup founded in 2016 developing physical assistance devices for people with reduced mobility. Incubated at Eurasanté center. Committed to social and solidarity economy principles.
- VipaliminorDigital health prevention tool developed to support personalized health prevention. Assesses lifestyle habits and provides recommendations on diet, physical activity, sleep, wellbeing, and daily behaviors.
- European Metropolis of Lille (MEL)coreRegional institutional partner represented on the Board of Directors through Vice-President Arnaud Deslandes for Economy, Research, University and Entrepreneurship.
- Hauts-de-France Regional CouncilcoreRegional institutional partner represented by Vice-President Manoëlle Martin on the Board of Directors. Supports regional health and research initiatives.
- Nord Departmental CouncilcoreDepartmental institutional partner represented by Councillor Charlotte Lecocq Parmentier on the Board of Directors.
- Laboratoires AniosminorCorporate sponsor of the Pasteur Institute Museum, illustrating collaboration between the institute and the economic world through sponsorship arrangements.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Institut Pasteur de Lille competitors and assessment
Company assessmentBroad incumbents
- INSERM: France's national institute for health and medical research jointly operates multiple research units with Institut Pasteur de Lille (UMR1011, UMR1167, UMR1177, UMR1190, UMR1283). It is a broader national incumbent in the same biomedical research domain.
- Karolinska Institutet: Sweden's medical university with deep research portfolio in metabolic disease, neurodegenerative disease, and public health. Comparable in translational research orientation and integration with clinical prevention and population health.
- CNRS: France's national scientific research center co-runs joint research units on the Lille campus (UMR9017, UMR9031, UMR9020) including the cancer and structural biology units. A direct institutional peer in basic biomedical research.
- Howard Hughes Medical Institute: Large US biomedical research organization supporting scientists across many institutions with a focus on discovery science. Comparable as a nonprofit foundation that combines intramural research, talent funding, and translational output.
Direct peers
- Helmholtz Centre for Infection Research (HZI): German research center focused on infectious disease research, antimicrobial resistance, and vaccine development. Directly comparable on the infectious-diseases and antibiotic-resistance research focus of Unit U1019 at Institut Pasteur de Lille.
- The Francis Crick Institute: A large UK biomedical research institute combining discovery science with translational and clinical collaboration. Comparable in scale (~1,500+ scientists), interdisciplinary disease focus, and integration with academic hospital partners.
- Max Planck Institute for Infection Biology: Germany's Max Planck society operates this institute on infection biology and immunology with significant overlap to Institut Pasteur de Lille's immunology, infection, and vaccine research activities.
- Institut Pasteur: The flagship Parisian Pasteur Institute shares the same Pasteur heritage, RIIP membership, public-utility nonprofit status, and integrated research-and-prevention mission. It is the most direct structural and historical peer of Institut Pasteur de Lille.
- Institut Pasteur de Madagascar: Member institute of the same RIIP network delivering research, training, and public health services in a different geography. Shares mission, governance philosophy, and Pasteur brand but focuses on tropical/communicable diseases.
Regional players
- Pasteur Institute of Iran: RIIP network member operating regional public-health, vaccination, and research services. Demonstrates how individual Pasteur institutes adapt the integrated research-plus-prevention model to local disease burdens.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Institut Pasteur de Lille social profiles
Digital presenceInstitut Pasteur de Lille compliance and trust
Trust signalCompliance2 records
Institut Pasteur de Lille financial estimates
Financial estimateRevenue estimate
Valuation estimate
Institut Pasteur de Lille leadership team
Management profileNumber of profiles
Institut Pasteur de Lille funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Institut Pasteur de Lille M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Institut Pasteur de Lille
What does Institut Pasteur de Lille do?
Institut Pasteur de Lille is a non-profit research foundation that conducts fundamental and applied biomedical research in infectious diseases (notably vaccinology and respiratory pathogens), nutrition/metabolic disorders (diabetes, obesity, cardio-metabolic disease), and neurodegenerative diseases (Alzheimer's and related dementias). It complements this research with a Center for Preventive Medicine that delivers individual health check-ups, a Clinical Investigation Center supporting clinical trials, and the SH2 center for human and social sciences, while also running training programs and public-health outreach actions.
Is Institut Pasteur de Lille a public or private company?
Institut Pasteur de Lille is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Institut Pasteur de Lille founded?
Institut Pasteur de Lille was founded in 1894. It employs 101 to 250 people.
Where is Institut Pasteur de Lille based?
Institut Pasteur de Lille is headquartered in Lille, France, in the Europe region.
How does Institut Pasteur de Lille make money?
Five revenue lines are on record. Donations and charitable contributions are the primary driver. The others are biotechnology company partnerships, prevention and healthcare services, corporate sponsorship and mecenat and institutional research funding.
Who are Institut Pasteur de Lille's main competitors?
Broad incumbents on record are INSERM, Karolinska Institutet, CNRS and Howard Hughes Medical Institute. Direct peers are Helmholtz Centre for Infection Research (HZI), The Francis Crick Institute, Max Planck Institute for Infection Biology, Institut Pasteur and Institut Pasteur de Madagascar. Pasteur Institute of Iran is listed as a regional player.
Does Institut Pasteur de Lille have an API?
No public API is recorded for Institut Pasteur de Lille.
What industry is Institut Pasteur de Lille in?
Institut Pasteur de Lille's product category is Biomedical Research and Preventive Healthcare Services. Its primary akta.pro industry code is HLAJAKAN, Global Health Research, Evidence & Technical Assistance Organizations, with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 541714 and its SIC code is 8000.